Abeona Therapeutics (ABEO) Cash from Financing Activities (2012 - 2026)

Abeona Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 132.83% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at $17.0 million (down 80.05% YoY), while the FY2025 annual figure was $26.0 million, down 74.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$2.2 million, down from $3.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $73.7 million in Q2 2024, with the low at -$2.2 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $6.6 million (2023), against an average of $14.1 million.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities jumped 636100.0% in 2024, then plunged 132.83% in 2026.
• Abeona Therapeutics' Cash from Financing Activities stood at $42.8 million in 2022, then slumped by 82.54% to $7.5 million in 2023, then fell by 28.83% to $5.3 million in 2024, then slumped by 31.99% to $3.6 million in 2025, then slumped by 161.48% to -$2.2 million in 2026.
• Business Quant data shows ABEO's Cash from Financing Activities at -$2.2 million in Q1 2026, $3.6 million in Q4 2025, and $5.2 million in Q3 2025.